Welcome to our dedicated page for Acumen Pharmaceuticals news (Ticker: ABOS), a resource for investors and traders seeking the latest updates and insights on Acumen Pharmaceuticals stock.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) is a clinical-stage biopharmaceutical company whose news flow centers on the development of sabirnetug (ACU193), a humanized monoclonal antibody targeting toxic soluble amyloid beta oligomers (AβOs) for the treatment of early Alzheimer’s disease. Company updates consistently highlight progress in its Phase 2 ALTITUDE-AD trial, scientific presentations, collaborations and financial disclosures.
Visitors to this ABOS news page can review press releases on key clinical milestones, such as enrollment updates and the initiation of the open-label extension portion of ALTITUDE-AD, as well as data readouts from the Phase 1 INTERCEPT-AD study and subsequent analyses. Acumen also reports on operational innovations in trial execution, including the use of a plasma pTau217 assay to streamline screening and reduce costs in its Phase 2 program.
In addition to clinical trial developments, Acumen regularly announces scientific findings presented at major Alzheimer’s and neurology conferences. These items include data on sabirnetug’s selectivity for AβOs over monomeric amyloid beta, biomarker results, and research on Enhanced Brain Delivery (EBD™) approaches in collaboration with JCR Pharmaceuticals using transferrin-receptor-targeting, blood–brain barrier-penetrating technology.
Investors and followers of ABOS will also find news related to corporate events, such as board appointments, strategic collaboration agreements and quarterly financial results, which are often accompanied by conference call and webcast details. This page provides a centralized view of Acumen’s public communications as it advances its AβO-targeted therapeutic programs for Alzheimer’s disease.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Acumen Pharmaceuticals (NASDAQ: ABOS) presented research at the AD/PD 2023 conference showcasing a human model using iPSC-derived excitatory neurons to study drug binding to amyloid beta oligomers linked to Alzheimer’s disease (AD). Key findings indicate oligomer size affects neuronal binding, underscoring the significance of oligomer preparation and antibody selection in assays. This research supports Acumen's clinical development of ACU193, a monoclonal antibody targeting toxic globular sAβOs, with patient enrollment completed for its Phase 1 INTERCEPT-AD trial. The poster presentation is scheduled for March 28 and will be accessible throughout the conference.
Acumen Pharmaceuticals (NASDAQ: ABOS) announced the completion of enrollment in its Phase 1 INTERCEPT-AD trial for ACU193, targeting early Alzheimer's disease, in February 2023, with topline results anticipated in Q3 2023. The company reported a cash balance of $193.4 million as of December 31, 2022, projected to sustain operations through 2025. R&D expenses surged to $32.4 million, up from $12.3 million in 2021, reflecting ongoing clinical trials. Despite a net loss of $42.9 million for 2022, a decrease from $100.6 million in 2021, the firm remains optimistic about its future developments, bolstered by FDA Fast Track designation for ACU193.